• ANJALI M. WANEGAONKAR Department Pharmaceutical Chemistry C. U. Shah College of Pharmacy, S. N. D. T. Women’s University, Sir Vithaldas Vidyavihar, Juhu Road, Santacruz (West), Mumbai 400049, Maharashtra, India
  • MILIND J. BHITRE Department Pharmaceutical Chemistry C. U. Shah College of Pharmacy, S. N. D. T. Women’s University, Sir Vithaldas Vidyavihar, Juhu Road, Santacruz (West), Mumbai 400049, Maharashtra, India
  • DILLIP ZAVERI Biocare Research India Pvt. Ltd.,1st Floor, Kanth Complex, Above New Limda Travels, Near Mahavir Jain Vidyalaya, Paldi Cross Road, Ahmedabad
  • SHRIRAM H. BAIRAGI Department Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, Kalyan, Maharashtra, India 421306



Angiogenesis, Indole chalcone, CAM assay


Objective: Synthesis of N-1 Substituted Indolylchalcone Hybrids and evaluation of anti-angiogenic activity using Chorioallantoic Membrane (CAM) Assay.

Methods: Claisen-schmidt reaction is used for the synthesis of 30 Indolylchalcone hybrids, it involves condensation of N-1 substituted indole-3-carboxaldehyde and N1 substituted 2-acetyl-benzimidazole. The phase transfer catalyst, a green catalyst such as anhydrous potassium carbonate (K2CO3) and PEG-400 are used in the alkylation and arylation. All synthesized indolylchalcone hybrids were evaluated for their antiangiogenic activity by in vivo-chorioallantoic membrane (CAM) assay method.

Results: The synthesized indolylchalcone compounds are evaluated. The morphometric study was carried out as described by Melkonian et al. (2002). The Compounds with code C-2, I-1, I-2 are showing the more potent effect on the dose-dependent assay of CAM. The compounds with code C-1, C-3, E-1 to E-3, M-1 and M-5 shows the significant activity, however, though the compounds with code B-1, B-2, CL-1 and A-5 were showing antiangiogenic effect at 0.1 µM, but does not show any significant activity on dose-dependent assay of CAM.

Conclusion: The synthesized Indolylchalcones as shown in the graph possess very good dose-dependent anti-angiogenic activities. The potency of anti-angiogenetic activity shows that methyl>Ethyl>Cl-benzyl>Benzyl>Isobutyl. 2-acetyl benzimidazole analogs have possible future scope to develop as potent angiogenesis inhibitors.


Download data is not yet available.


1. Venkateswaran A, Reddy Y, Sonar V, Muthusamy V, Crooks P, Freeman M, et al. Antiangiogenic properties of substituted (Z)-(±)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives. Bioorg Med Chem Lett 2010;20:7323–6.
2. Huang L, Shih M, Chen H. Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-angiogenic agents. Bioorganic Med Chem 2006;14:528–36.
3. Nagaraju G, Zhu S, Ko J. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett 2015;357:557–65.
4. Oklu R, Walker T, Wicky S, Hesketh R. Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 2010;21:1791–805.
5. Wen Hui Yang, Jun Xu, Jian Bing Mu, Jun Xie. Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Diseases Translational Med 2017;3:33-40.
6. Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J Basic Med Sci 2012;15:1110–26.
7. Gotink K, Verheul H. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action. Angiogenesis 2010;13:1–14.
8. Saraswati S, Agrawal S. Brucine, an indole alkaloid from strychnos nux-vomica, attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo. Cancer Lett 2013;332:83–93.
9. Lee H, Banskota S, Kim D, Been J, Jin Y, Gautam J, et al. Synthesis and antiangiogenic activity of 6-amido-2,4,5-trimethylpyridin-3-ols. Bioorganic Med Chem Lett 2014;24:3131–6.
10. He H, Wang X, Shi L, Yin W, Yang Z, Liang Y. Synthesis, antitumor activity and mechanism of action of novel 1,3-thiazole derivatives containing hydrazide-hydrazone and carboxamide moiety. Bioorg Med Chem Lett 2016;14:3263-70.
11. Christodoulou M, Liekens S, Kasiotis K, Haroutounian S. Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity. Bioorg Med Chem 2010;18:4338–50.
12. Roopashree R, Mohan C, Swaroop T, Jagadish S, Rangappa K. Synthesis, characterization, and in vivo biological evaluation of novel benzimidazoles as potential anticancer agents. Asian J Pharm Clin Res 2014;7:309–13.
13. Nagarajan S, Majumder S, Sharma U, Rajendran S, Kumar N, Chatterjee S, et al. Synthesis and anti-angiogenic activity of benzothiazole, benzimidazole containing phthalimide derivatives. Bioorganic Med Chem Lett 2013;23:287–90.
14. Kumar D, Kumar N, Akamatsu K, Kusaka E, Harada H, Ito T. Synthesis and biological evaluation of indolyl chalcones as antitumor agents. Bioorganic Med Chem Lett 2010;20:3916–9.
15. Kumar D, Maruthi Kumar N, Tantak M, Ogura M, Kusaka E, Ito T. Synthesis and identification of ?-cyano bis(indolyl)chalcones as novel anticancer agents. Bioorganic Med Chem Lett 2014;24:5170–4.
16. Shi J, Xiao Z, Ihnat M, Kamat C, Pandit B, Hu Z, et al. Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorganic Med Chem Lett 2003;13:1187–9.
17. Melkonian G, Munoz N, Chung J, Tong C, Marr R, Talbot P. Capillary plexus development in the day five to day six chick chorioallantoic membrane is inhibited by cytochalasin D and suramin. J Exp Zool 2002;292:241–54.
18. Pandit R, Anil A, Lali A, Indap M. Evaluation of antiangiogenic activity through tubulin interaction of chloroform fraction of the feather star, Lamprometra palmata palmata. Indian J Mar Sci 2009;38:28–37.



How to Cite

WANEGAONKAR, A. M., M. J. BHITRE, D. ZAVERI, and S. H. BAIRAGI. “CONSISE SYNTHESIS AND POTENTIAL ANTI-ANGIOGENIC ACTIVITY OF N-1 SUBSTITUTED INDOLYLCHALCONE HYBRIDS ON CHORIOALLANTOIC MEMBRANE (CAM) ASSAY”. International Journal of Current Pharmaceutical Research, vol. 13, no. 1, Jan. 2021, pp. 81-86, doi:10.22159/ijcpr.2021v13i1.40822.



Original Article(s)